NYSE:HAEMedical Equipment
Haemonetics (HAE) Balances Softer Interventional Sales With Buybacks – What Story Does Guidance Tell?
In early February 2026, Haemonetics Corporation reported third-quarter fiscal 2026 results showing lower sales of US$338.97 million year over year but higher net income of US$44.74 million, and issued guidance calling for first-quarter 2026 revenue of US$300 million–US$310 million and full-year 2026 revenue of US$1.22 billion–US$1.26 billion.
Management highlighted continuing weakness in Interventional Technologies against resilient plasma and blood management performance, while confirming...